group 21 to 25

clinical stage immunology company

targeted monoclonal antibodies

late stage clinical biopharma company

identifying, aquiring and accekerating the development and commercialization of medecines for diseases related to excess activation of the immune system

clinical stage biotech

engineered monoclonal antibodies (mAbs) with potential best-in-class profiles to overcome current therapy limitations by optimizing half-life, maximizing antibody recycling, and decreasing the dosing for patients.

late stage clinical biotech

focused on developing drugs to improve immune and inflammatoty diseases to set up new standards care for unmet medical needs

makes antiviral treatmnets

-Monoclonal antibody platform with AI-led protein engineering capabilities ○ T cell-based viral vector platform (Induce T cell response with engineered HCMV) ○ siRNA (in combination with antibodies)

clinical stage biotech company commited to the discovert, development and commercialization of orally availabel direct acting antiviral therapies

Nucleus(t)ide analogs and prodrugs targeting RNA-dependent RNA polymerase of +ssRNA viruses (mainly COVID-19, HCV, Dengue but were previously working on an RSV drug).

Leading biotechnology company founded and led by physician-scientists whose medicines and pipelines are designed to treat a variety of serious diseases such as eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, hematologic conditions, infectious diseases, and rare diseases

fully human therapeutoc antibodies and bispecific antibodies aka velocisuite tech

o is a clinical-stage biotechnology company working to transform patient health by delivering innovative immunology therapeutics with a focus on addressing unmet medical needs in autoimmune and inflammatory diseases.

Coupling mammalian cell surface display with somatic hypermutation (SHM) for the discovery and maturation of human antibodies

clinical stage biopharmaceutical comp

small molecules trating the symtoms of epilepsy and other cns disorders

s a biotechnology company which pioneers in transformative RNA medicines

PRISMTM is an oligonucleotide platform combining four RNA-targeting modalities (editing, splicing, siRNA and antisense).

Clinical-stage biopharmaceutical company focusing on treatment of neurodegenerative and lysosomal storage diseases.

Proprietary antibody transport vehicles (ATVs) and enzyme transport vehicles (ETVs) with engineered BBB receptor binding into an Fc domain (Transferrin receptor, TfR, highly expressed) thus actively transporting molecules across the BBB through receptor-mediated transcytosis (RMT).

clinical stage biopharmaceutica company

small molecules that modify splicing, ferroptosis and inflammation